David A. Siegel Athira Pharma, Inc. Transaction History
Two Sigma Advisers, LP
- $42.5 Billion
- Q1 2024
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Athira Pharma, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 369,500 shares of ATHA stock, worth $949,614. This represents 0.0% of its overall portfolio holdings.
Number of Shares
369,500
Previous 298,600
23.74%
Holding current value
$949,614
Previous $725,000
39.59%
% of portfolio
0.0%
Previous 0.0%
Shares
14 transactions
Others Institutions Holding ATHA
# of Institutions
83Shares Held
22.3MCall Options Held
77.1KPut Options Held
42.4K-
Perceptive Advisors LLC New York, NY5.4MShares$13.9 Million0.31% of portfolio
-
Baker Bros. Advisors LP New York, NY3.15MShares$8.11 Million0.11% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.63MShares$4.2 Million0.0% of portfolio
-
Propel Bio Management, LLC Los Angeles, CA1.49MShares$3.84 Million2.38% of portfolio
-
Simplify Asset Management Inc. New York, NY1.49MShares$3.84 Million0.26% of portfolio
About Athira Pharma, Inc.
- Ticker ATHA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 37,817,700
- Market Cap $97.2M
- Description
- Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. The company's lead product candidate is ATH-1017, a blood brain barrier-penetrating, small molecule HGF/MET positive modulator that is in LIFT-AD Phase 3 and ACT-AD Phase 2 clinical tri...